Pharmaceuticals firm Fujifilm Diosynth Biotechnologies saw a significant leap in revenue and profits as work to double the size of its Teesside operation continues.
The contract manufacturer - which makes the Novavax Covid-19 vaccine at its Billingham site - filed accounts for the year to the end of March 2022 which show operating profits increased from £13.1m to £21.5m as revenues ramped up from £118.7m to £145.2m. Fujifilm, which now employs more than 1,000 people on Teesside, said the performance was down to buoyancy in the mammalian and process development sectors.
In 2021 plans were announced to spend £400m at Billingham in a bid to create the largest multi-modal biopharmaceutical manufacturing site in the UK, creating an additional 350 jobs. The expanded facility is expected to be operational later this year and will bring increases in its gene therapy production, cell culture capacity and microbial fermentation output.
